A unique kindred manifesting medullary thyroid carcinoma and cornea1 nerve thickening without other aspects of the multiple endocrine neoplasia syndrome (MEN) was analyzed by linkage analysis using four highly polymorphic (CA), repeat markers (sTCL-1, DlOS141,ZNF22, and sJRH-1). Additionally, the RET protooncogene was examined for specific mutations by DNA sequence analyses in all affected family members. Screening of 11 family members spanning 4 generations revealed 7 subjects with cornea1 nerve thickening; of these subjects, 3 had abnormal pentagastrin-stimulated calcitonin studies, and these 3 subjects were each found to have C-cell hyperplasia or medullary thyroid carcinoma at surgery. Linkage analysis showed cosegregation of alleles (as defined by the above markers), with the presence of both cornea1 nerve thickening and medullary thyroid carcinoma/C-cell hyperplasia (maximum LOD score, 2.69; consistent with, but not proving linkage). DNA sequence analysis showed that none of the affected individuals had mutations in either exon 10 or 11, or in exon 16 of the RET protooncogene, regions where mutations have been described for MEN type 2A (MEN-2A) and MEN-2B families, respectively. Thus, compared to the defined syndromes of MEN-2A and MEN-SB, this kindred appears to represent a true clinical overlap syndrome whose genetic basis may be distinct from these two syndromes. (J Clin Endocrinol Metab 80: 289-293, 1995) 
showed cosegregation of alleles (as defined by the above markers), with the presence of both cornea1 nerve thickening and medullary thyroid carcinoma/C-cell hyperplasia (maximum LOD score, 2.69; consistent with, but not proving linkage). DNA sequence analysis showed that none of the affected individuals had mutations in either exon 10 or 11, or in exon 16 of the RET protooncogene, regions where mutations have been described for MEN type 2A (MEN-2A) and MEN-2B families, respectively. Thus, compared to the defined syndromes of MEN-2A and MEN-SB, this kindred appears to represent a true clinical overlap syndrome whose genetic basis may be distinct from these two syndromes. (J Clin Endocrinol Metab 80: 289-293, 1995) M ULTIPLE endocrine neoplasia type 2 (MEN-2) is an autosomal dominant cancer syndrome which has classically been divided into two subtypes: MEN-2A and MEN-2B. The characteristic features of MEN-2A include medullary thyroid carcinoma (MTC), pheochromocytoma, and primary hyperparathyroidism. MEN-2B is characterized by MTC, pheochromocytoma, and multiple mucosal neuromas. Other features of MEN-2B include enlarged nerves of the gastrointestinal tract (ganglioneuromatosis), marfanoid habitus (with pectus excavatum, slipped femoral epiphysis, and long thin extremities), and cornea1 nerve thickening (CNT). In addition to MEN-2A and -2B, families have also been described with familial MTC (FMTC) alone, without pheochromocytomas or primary hyperparathyroidism (for review, see Ref. 1) .
Several examples of overlap syndromes between MEN-2A and MEN-2B have been reported (2-4). CNT, although characteristic of MEN-2B, has also been noted in patients with MEN-2A who lack any of the other characteristic stigmata of MEN-2B (3, 5). In addition, Lacroix et al. (2) have described families with individual members who have either MEN-2A or MEN-2B. Several families with MEN-2A and a characteristic skin lesion, cutaneous lichen amyloidosis, have also been described (6-8). These clinical examples suggest that although MEN-2A and -2B are, in general, distinct syndromes, there may be some individuals and/or families with features that overlap the two syndromes or have MEN-2A and other associated anomalies, such as cutaneous amyloidosis.
Genetic linkage studies have mapped the genes for MEN-2A, MEN-2B, and FMTC to chromosome lOq11.2, where the RET protooncogene has also been mapped (9-12). The RET protooncogene encodes a receptor tyrosine kinase, which is expressed in MTC and pheochromocytoma and at lower levels in normal human thyroid (13). Recently, missense mutations in exon 10 or 11 of the RET gene have been reported in greater than 95% of MEN-2A families studied (14-16). All of the mutations described thus far result in nonconservative amino acid changes involving the cysteine-rich portion of the extracellular domain of . Similar mutations have been described in 4 families with FMTC alone (15). Recently, families with cutaneous lichen amyloidosis and MTC have also been found to have RET mutations in exon 11 (17). Of 48 MEN-2B families examined to date, none manifested mutations in exon 10 or 11 of the RET gene (14-16,lB). However, recent genetic analysis of individuals with MEN-2B has revealed an amino acid substitution in exon 16 of the RET gene. Hofstra et al. (19) documented a codon 918 mutation in exon 16 of the RET gene in 9 MEN-2B patients, whereas Eng et al. (20) described a similar mutation in 26 of 28 MEN-2B patients.
In the present study we report a kindred with the occurrence of MTC and CNT documented in three generations. Other than CNT, these individuals lacked any of the other characteristic stigmata of MEN-2B. These findings suggested the possibility of a clinical overlap syndrome between MEN-2A and -2B, or perhaps a variant of MEN-2B, and prompted further clinical and genetic analysis of this kindred. JCE & M . 1995 Vol80. No 1
Case Report
The kindred ( Fig. 1 ) was first identified when the 65-yr-old proband (11.2) was seen in the Eye Department of the Mayo Clinic during the course of a general medical evaluation for nonspecific neurological symptoms (mild ataxia and urinary incontinence). Thickened cornea1 nerves were recognized on routine slit lamp biomicroscopy (Fig. 2) (15) . Because of the known association between thickened cornea1 nerves and the MEN syndromes, an investigation was initiated to search for evidence of medullary thyroid carcinoma.
The basal calcitonin (CT) level was 40 rig/L (see Materials and Mefhods for description of assay and normal values). After stimulation with pentagastrin, his CT value was 1000 rig/L. These findings supported the clinical diagnosis of MTC. There were no other findings to suggest MEN-2B (the patient had neither mucosal neuromas nor a Marfanoid habitus). The serum calcium level and urinary metanephrine excretion were normal. The patient's neurological symptoms stabilized without specific treatment; further evaluation and therapy focused on his thyroid abnormality.
Thyroidectomy was performed, and multifocal (6) MTCs, ranging in size from 0.2-0.4 cm were identified. The presence of bilateral multifocal MTC suggested a familial form of MTC (MEN-2A, MEN-2B, or FMTC), and the finding of CNT suggested either an overlap syndrome between MEN-2A and -2B or a MEN-2B variant. Therefore, family screening of 11 members spanning 4 generations was performed to search for MTC, CNT, and other components of the MEN-2 syndromes ( Fig. 1) . Evaluation for MTC included determination of basal and pentagastrin-stimulated CT concentrations. CNT was evaluated by slit lamp ophthalmic examination (5).
I ? 1
Other screening studies included blood pressure measurement, examination for mucosal neuromas, fasting serum calcium level, and urinary metanephrine excretion.
CT assay CT concentrations were measured by a sensitive extraction assay method (21) with a sensitivity of 2 rig/L. In our laboratory, normal basal CT values for males were less than 19 rig/L; those for females were less than 14 rig/L. Normal pentagastrin-stimulated CT values for males were less than 110 rig/L; those for females were less than 30 rig/L. Borderline values were defined as a greater than 20% elevation above normal basal values at baseline or after stimulation.
Materials
and Methods
DNA extraction
High mol wt DNA was isolated from peripheral blood leukocytes (huffy coat) using an Applied Biosystem 340A DNA Extractor (Applied Biosystem, Foster City, CA) according to the manufacturer's instructions.
Molecular markers
Polymerase chain reaction VCR) amplification was performed using the oligonucleotide primers described by Howe et nl. (22) for sJRH-1 and sTCL-1 and by Love et nl. (23, 24) demonstrating markedly thickened cornea1 nerves characteristic of those seen in the affected subjects of our kindred.
conditions included denaturation for 30 s at 94 C, annealing for 30 s at 55 C. and extension for 30 sat 72 C for 30 cvcles. The PCR uroducts were electrophoresed on 6% denaturing poly&ylamide sequencing gels, dried on a vacuum slab dryer, and exposed to Kodak XAR film (Eastman Kodak, Rochester, NY) at -70 C overnight.
Linkage analyses, including two-point and multipoint analyses, were performed using the program Linkage (version 5.1) (25) . A gene frequency of 1 in 50,000 was assumed for the disease gene, although gene frequencies of 50-100 times smaller and larger than this were also tried, but had minimal effect on the LOD score (measure of genetic linkage defined as the log,, ratio of the probability that the data would have arisen if the loci were linked to the probability that the data could have arisen from unlinked loci; conventional threshold for declaring Linkage is 3.0). Penetrance was assumed to be lOO%, and individuals with CNT were considered affected. No individuals had MTC, C-cell hyperplasia, abnormal CT values (basal or pentagastrin-stimulated), or even borderline CT values without CNT. Allele frequencies of the polymorphic markers were assumed to be equal for each marker.
Sequence analysis PCR amplification of exons 10 and 11 of the RET protooncogene was uerformed usine the olieonucleotides Ret A (5'-TCCGGGGCAGCAT-?GlT-3') and R%T B (5'?lTGAAGGCATCCkCGGAGA-3'1, whereas amplification of exon 16 was performed using the oligonucleotide FRET 16 (5'AGGGATAGGGCCTGGGCTTC-3') and RRET 16 (5'-TAACCTC-CACCCCAA-GAGAG3') (19) . Each reaction contained 250 ng genomic DNA, 10 pmol/L of each primer, 200 pmol/L dNTP, 2 mmol/L MgCI,, and 0.25 PL Tuq polymerase in a final volume of 25 PL. For amplification of exons 10 and 11, the reaction conditions included preheating for 2 min at 95 C, denaturing for 30 s at 94 C, annealing for 30 s at 65 C, and extension for 30 s at 72 C, for 30 cycles. For exon 16, the PCR conditions included denaturing for 30 s at 94 C, annealing for 30 s at 55 C, and extension for 30 s at 72 C for 30 cycles. PCR products were directly sequenced by using the femtomole sequencing kit (Promega, Madison, WI) according to the manufacturer's instructions. The sequencing primer was Ret D (5'-TTGGGACCTCAGATGTGCTGTT-3') for exon 10, CRT 19B (5'-GCATACGCAGCCTGTACCC-3') for exon 11, and FRET 16 for exon 16. Sequencing conditions were preheating for 2 min at 95 C, denaturing for 30 s at 95 C, and annealing/extension for 30 s at 70 C for 30 cycles. The sequencing PCR products were electrophoresed through a 6% polyacrylamide-7 mol/L urea gel. The gel was vacuum dried for 1 h and then exposed to Kodak XAR film for 2-12 h at room temperature.
Sequence information for the RET protooncogene was kindly provided by Dr. Bruce Ponder (University of Cambridge, Cambridge, MA).
Results
Clinical studies Figure 1 shows the pedigree of the kindred. Generation I had no historical evidence of MEN-2A or MEN-2B. As depicted in Fig. 1,4 of 11 family members had abnormal pentagastrin-stimulated CT levels (3 were frankly abnormal and 1 was borderline). The 3 patients with frankly abnormal pentagastrin stimulation studies underwent thyroidectomy with the following findings: MTC (11.2), microscopic MTC plus C-cell hyperplasia (111.71, and C-cell hyperplasia (IV.21). The latter finding of C-cell hyperplasia alone was noted in a 12-yr-old female. Ophthalmic evaluation showed CNT in 7 of 11 subjects; this included the 3 members with abnormal pentagastrin stimulation studies (and surgically proven Ccell hyperplasia or MTC) and 1 member with a borderline pentagastrin stimulation study, who did not undergo surgery. No family member had findings to suggest hyperparathyroidism, pheochromocytoma, mucosal neuromas, or Marfanoid body habitus.
Molecular markers
Linkage analysis using a panel of polymorphic markers known to be linked to the MEN-2 locus (23, 261 showed cosegregation of alleles (haplotype 5622) with the presence of both CNT and MTC/C-cell hyperplasia (Fig. 1) . For the linkage analysis, CNT was used as the indication of an affected individual. For the two-point linkage analyses, the maximum likelihood estimate of the recombination fraction between the disease locus and marker locus was zero for each marker, with maximum LOD scores of 1.46 for sTCL-1,2.69 for DlOS141, 2.09 for ZNF22, and 2.69 for sJRH-1. For multipoint linkage analysis, we used the sex-averaged linkage map [distance in centromeres (CM)] of Gardner et al. (26) : sTCL-1 (1.5 CM), DlOS141 (2.7 CM), ZNF22 (1.5 CM), and sJRH-1. The maximum LOD score was 2.69 regardless of whether this map was used or a map with interval distances of 3, 3, and 2 CM, respectively. In our pedigree there were effectively nine informative meioses, and the markers DlOS141 and sJRH-1 were fully informative, which explains why the maximum LOD scores for these two markers agree with the maximum LOD score for the multipoint analyses. Because the conventionally accepted LOD score for establishing linkage is 3.0 (or 1OOO:l odds against the findings being due to chance alone), the LOD score of 2.69 (or 5OO:l odds against chance findings) is consistent with but does not unequivocally prove linkage in this kindred.
DNA sequence analysis showed that none of the affected individuals had mutations in either exon 10 or 11, or in exon 16 of the RET protooncogene. Control DNA from a patient with MEN-2B demonstrated the expected T+C transition at codon 918 (19,201 (data not shown) . These data thus suggest that this MEN variant maps to the same region of chromosome 10 as MEN-2A and MEN-2B, but is not associated with the specific mutations that have been noted for MEN-2A or -2B.
Discussion
Clinically, this kindred demonstrates the familial occurrence of MTC and CNT without other stigmata classically found in either MEN-2A or -2B. With only these data, the family could be considered a variant of MEN-2A, MEN-2B, or FMTC. The distinction is important, because the natural history of MTC differs among the syndromes, with MEN-2B patients having an earlier age of onset (27) and, therefore, warranting earlier and more aggressive screening. In addition, distinguishing among the MEN syndromes allows a tailored screening process of those disorders known to occur in each syndrome. To screen for CNT, it is important that the corneas be examined with slit lamp biomicroscopy, as a naked eye evaluation will not reveal CNT. Although the finding of CNT in our proband was the first of any MEN stigmata to be noted and, therefore, led to the diagnosis of MTC, we cannot recommend routine screening for CNT in all MEN-2 families.
MTC or C-cell hyperplasia was diagnosed at variable ages in this kindred: multifocal MTC at age 66 yr in the proband, patient 11.2, and C-cell hyperplasia at age 12 yr in patient IV.21. These findings differ from both MEN-2B, in which MTC is often diagnosed at a very early age (27, 28) , and FMTC, in which the MTC typically has a relatively late age of onset (1).
Genetic linkage studies in this kindred using polymorphic markers in the region of the MEN-2 gene strongly suggest linkage between these loci and disease expression (either CNT or MTC/C-cell hyperplasia plus CNT). Of note, three patients in generation III (patients 111.1, 111.2, and 111.4, ages ranging from 42-47 yr) had CNT documented by ophthalmic examination and carried the haplotype 5622 associated with CNT/MTC, but had negative screening tests for MTC (normal basal and pentagastrin-stimulated CT levels). Given the variable age of onset for C-cell hyperplasia/MTC noted in this kindred, these patients warrant further follow-up for MTC with repeated pentagastrin stimulation tests. Subject IV.20 (age 14 yr) should undergo similar or more stringent follow-up for MTC. Additionally, other members of generation lV, particularly those with affected parents, should undergo screening studies, including slit lamp biomicroscopy for CNT and basal and pentagastrin-stimulated CT assessments.
In contrast to MEN-2A and FMTC, in which RET protooncogene mutations involving primarily cysteine residues in exon 10 or 11 have been identified in a high percentage of families (14) (15) (16) 18) , the present kindred with familial MTC and CNT did not manifest such mutations. This finding is similar to the MEN-2B families studied to date. As noted previously, none of the 48 MEN-2B families studied in several independent reports had mutations involving exon 10 or 11 of . Two recent reports document a mutation in the RET protooncogene exon 16 codon 918 in MEN-2B patients (19, 20) . Analysis of our kindred failed to reveal any mutation in exon 16 of RET.
In summary, the present studies provide a clinical and molecular genetic description of a kindred with FMTC and CNT, a syndrome not previously reported, representing a clinical overlap MEN syndrome or, perhaps, a variant of MEN-2B. By linkage analysis, this MEN variant appears to map to the same region of chromosome 10 as MEN-2A and -28. However, more detailed analysis failed to reveal any mutation in exon 10 or 11 [as described for MEN-2A (14-16, IS)] or in exon 16 [as described for MEN-2B (19, 20) ]. Further studies of the RET protooncogene in this kindred may identify a unique mutation resulting in this particular phenotype. Alternatively, this variant MEN syndrome may be due to a mutation involving a closely linked gene. 18.
